Board of Lupin approves acquisition of a portfolio of brands of Anglo-French Drugs Industries

21 Jan 2022 , 01:33 AM

The Board of Lupin at its meeting held on 17 January 2022 has approved the acquisition of a portfolio of brands including all rights and interests associated with such products of Anglo-French Drugs Industries and its associates subject to approval of their shareholders to strengthen the Companys portfolio in the Vitamins Minerals and Supplements and CNS segments The transaction entails a lumpsum consideration of about Rs 325 crore including working capital normalised inventory of three months amounting to Rs 9 crore approx on a cash and debt-free basis